Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence

References

• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57.
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007;132:1979–1998.
   PubMed Web of Science ®Google Scholar
• Swain MG, Lai M, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with Peginterferon Alfa-2a and Ribavirin. Gastroenterology. 2010;139:1593–1601.
   PubMed Web of Science ®Google Scholar
• Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–288.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed Cryoglobulinemia: meta-analysis of clinical studies. J Med Virol. 2013;85:1019–1027.
   PubMed Web of Science ®Google Scholar
• Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408–417.
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M, Feld JJ, Zeuzem S, et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87–S99.
   Google Scholar
• San Miguel R, Gimeno-Ballester V, Mar J. Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Rev Pharmacoecon Outcomes Res. 2014;14:387–402.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
   PubMed Web of Science ®Google Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414–426.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403–413.
   PubMed Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669–79e3.
   PubMed Web of Science ®Google Scholar
• You DM, Pockros PJ. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013;14:2581–2589.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;61(1 Suppl):S45-S57.
   Google Scholar
• AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 655 Hepatology (Baltimore, Md). 2015;62:932–954.
   Google Scholar
• European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
   Google Scholar
• Committee for Medicinal Products for Human Use. Product information: Sovaldi. EMA. 2014.
   Google Scholar
• Committee for Medicinal Products for Human Use. Product information: Olysio. EMA. 2014.
   Google Scholar
• Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, et al. Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet. 2016;55(2):197–208.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Assessment report: Olysio. EMA. 2014.
   Google Scholar
• Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–16.
   PubMed Web of Science ®Google Scholar
• Bae A, Sun SC, Qi X, et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother. 2010;54:5288–5297.
   PubMed Web of Science ®Google Scholar
• Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in phase IIb/III studies. J Hepatol. 2015;62(5):1008–1014.
   PubMed Web of Science ®Google Scholar
• Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56:3359–3368.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.
   PubMed Web of Science ®Google Scholar
• Costantino A, Spada E, Equestre M, et al. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J. 2015;12:186.
   PubMed Web of Science ®Google Scholar
• Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet (London, England). 2008;371:281–283.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed). 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.
   PubMed Web of Science ®Google Scholar
• Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol. 2009;62(12):1253–1260.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology. 2016;64(2):360–369.
   PubMed Web of Science ®Google Scholar
• Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related child’s class A cirrhosis. Gastroenterology. 2015;148(4):762–2.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64:370–380.
   PubMed Web of Science ®Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans. Aliment Pharmacol Ther. 2015;42(5):559–573.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150(2):419–429.
   PubMed Web of Science ®Google Scholar
• Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62(3):715–725.
   PubMed Web of Science ®Google Scholar
• Shiffman ML, James AM, Long AG, et al. Treatment of Chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or Ribavirin. Am J Gastroenterol. 2015;110(8):1179–1185.
   PubMed Web of Science ®Google Scholar
• Aqel BA, Pungpapong S, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology. 2015;62(4):1004–1012.
   PubMed Web of Science ®Google Scholar
• Deterding K, Höner Zu Siederdissen C, Port K, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42(7):889–901.
   PubMed Web of Science ®Google Scholar
• Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61(6):1880–1886.
   PubMed Web of Science ®Google Scholar
• Brown RS Jr., O’Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-World experience from the hepatitis C therapeutic registry and research network. Liver Transplant. 2016;22(1):24–33.
   PubMed Web of Science ®Google Scholar
• Pillai AA, Wedd J, Norvell JP, et al. Simeprevir and sofosbuvir (sim-sof) for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection: a real world (transplant) hepatology practice experience. Am J Gastroenterol. 2016;111(2):250–260.
   PubMed Web of Science ®Google Scholar
• Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transplant. 2015;21(6):823–830.
   PubMed Web of Science ®Google Scholar
• Saab S, Greenberg A, Li E, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015;35(11):2442–2447.
   PubMed Web of Science ®Google Scholar
• Punzalan CS, Barry C, Zacharias I, et al. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant. 2015;29(12):1105–1111.
   PubMed Web of Science ®Google Scholar
• Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infectious Diseases. 2015;47(12):924–929.
   PubMed Web of Science ®Google Scholar
• Gilmore J, Lynn K, Breen D, et al. Effectiveness of sofosbuvir/simeprevir for HIV/HCV patients in clinical practice. Top Antivir Med. 2015;23:281.
   Google Scholar
• Hézode C, Chevaliez S, Scoazec G, et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. 2016;63(6):1809–1816.
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Kozbial K, Freissmuth C, et al. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Aliment Pharmacol Ther. 2015;42:707–718.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
   PubMed Web of Science ®Google Scholar
• Afdhal N. A fixed-dose combination of sofosbuvir and ledipasvir for hepatitis C virus genotype 1. Gastroenterol Hepatol. 2014;10:815–817.
   Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. New England J Med. 2014;370(17):1594–1603.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Yoshida EM, Ghalib RH, et al. Impact of baseline albumin levels in a phase 3 study (OPTIMIST-2) of 12 weeks of simeprevir (SIM) plus sofosbuvir (SOF) in treatment-naïve or-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Hepatology. 2015;62:717A–8A.
   Google Scholar
• Mar J, Mar-Barrutia L, Gimeno-Ballester V, et al. Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis. Medicina Clinica. 2016;146(2):61–64.
   PubMed Web of Science ®Google Scholar
• Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–697.
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–713.
   PubMed Web of Science ®Google Scholar
• Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–713.
   PubMed Web of Science ®Google Scholar